Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Operations: 2009-2024

Historic Cash from Operations for Capricor Therapeutics (CAPR) over the last 16 years, with Dec 2024 value amounting to -$40.0 million.

  • Capricor Therapeutics' Cash from Operations fell 69.11% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.0 million, marking a year-over-year decrease of 65.90%. This contributed to the annual value of -$40.0 million for FY2024, which is 56.25% down from last year.
  • According to the latest figures from FY2024, Capricor Therapeutics' Cash from Operations is -$40.0 million, which was down 56.25% from -$25.6 million recorded in FY2023.
  • Capricor Therapeutics' Cash from Operations' 5-year high stood at $4.9 million during FY2022, with a 5-year trough of -$40.0 million in FY2024.
  • Moreover, its 3-year median value for Cash from Operations was -$25.6 million (2023), whereas its average is -$20.2 million.
  • Per our database at Business Quant, Capricor Therapeutics' Cash from Operations soared by 129.25% in 2022 and then slumped by 620.61% in 2023.
  • Capricor Therapeutics' Cash from Operations (Yearly) stood at -$10.1 million in 2020, then tumbled by 67.18% to -$16.8 million in 2021, then surged by 129.25% to $4.9 million in 2022, then plummeted by 620.61% to -$25.6 million in 2023, then crashed by 56.25% to -$40.0 million in 2024.